The UK Medicines and Healthcare Products Regulatory Authority (MHRA for its English acronym) approved it this Monday. first bivalent vaccine covid19, It is effective against both the original variant of SARS-CoV-2 and Ómicron.
Specifically, a update vaccine It is produced by the American company Moderna.and is approved for supplemental doses in adults “after verifying that it meets standards of safety, quality and efficacy” according to the British regulatory agency.
As they explain, with each dose of the “Spikevax bivalent Original/Omicron” booster vaccine, half (25 micrograms) of the vaccine targets the original strain of the virus and the other half (25 micrograms) Omicron, as of 2020.
The MHRA’s decision is based on data from a clinical trial showing that a Moderna bivalent vaccine booster induced “a potent immune response against both Omicron (BA.1) and the original 2020 strain.”
effective against Omicron BA.4 and BA.5
Similarly, bivalent vaccine has also been found to induce a good immune response to the vaccine. Sub-variants of Omicron BA.4 and BA.5.
When it comes to side effects, they have been found to be the same as those triggered by the original booster dose of Moderna and are generally mild. In this sense, no serious security problem has been identified.
MHRA Chief Executive Officer Dr. “I am pleased to announce the approval of the Moderna bivalent booster vaccine, which provides a robust immune response against the Omicron BA.1 variant and the original 2020 strain in clinical trial,” said June. Rain.
Although he admits First-generation vaccines against Covid-19 ‘continue to save lives’“assures that this bivalent vaccine provides a “more refined tool” in protecting against this disease “as the virus continues to evolve.”
Professor Sir Munir Pirmohamed, chairman of the UK Commission for Medicinal Products for Human Use, said the injection “represents the next step in the development of vaccines to combat the virus, due to its ability to cause a wider range of disease”. More immune response than the original vaccine.
In front of the British agency EMA
In this way, the United Kingdom communicated its decision to the EU. European Medicines Agency (EMA for its English acronym) announced in mid-June that it had begun an ongoing review of both Moderna’s bivalent vaccine version and Pfizer and BioNTech, which had shown promising results.
In fact, last week, Pfizer and BioNTech reported that their vaccines adapted to the BA.1 and BA.4/5 variants will not arrive until October 2022, “in time for the fall booster vaccine campaigns.”
Source: Informacion
